EntryPoint Capital’s Cogent Biosciences COGT Stock Holding History

EntryPoint Capital’s Portfolio COGT Stock Details COGT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$430K	Hold	11,123	–	–	0.1%	381
2026 Q1	$428K	Buy	+11,123	New	+$411K	0.13%	314
2025 Q2	–	Sell	-28,005	Closed	-$168K	–	648
2025 Q1	$168K	Sell	28,005 -24,341	-47%	-$191K	0.08%	572
2024 Q4	$408K	Buy	+52,346	New	+$522K	0.17%	197
2024 Q3	–	Sell	-25,137	Closed	-$212K	–	762
2024 Q2	$212K	Sell	25,137 -6,155	-20%	-$46.7K	0.1%	378
2024 Q1	$210K	Sell	31,292 -1,751	-5%	-$10.8K	0.19%	100
2023 Q4	$194K	Buy	+33,043	New	+$253K	0.19%	102

Other funds holding COGT

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Jupiter Topco New York $245B AUM

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

EntryPoint Capital's COGT Position: Q2 2026 in Review

EntryPoint Capital held its Cogent Biosciences (COGT) position steady in Q2 2026 at 11,123 shares worth $430K. The position accounts for 0.1% of the portfolio, ranked #381.

EntryPoint Capital first reported a position in COGT in Q4 2023 and has held it in 7 quarters since. 324 funds tracked by Wall St. Rank hold COGT as of Q2 2026.

EntryPoint Capital held 11,123 shares of Cogent Biosciences worth $430K as of Q2 2026.
EntryPoint Capital left its Cogent Biosciences share count unchanged in Q2 2026.
Cogent Biosciences made up 0.1% of EntryPoint Capital's portfolio in Q2 2026, its #381 holding.
EntryPoint Capital first reported a position in Cogent Biosciences in Q4 2023 and has held it in 7 quarters since.
324 funds tracked by Wall St. Rank held Cogent Biosciences as of Q2 2026.

Based on EntryPoint Capital's 13F filing for Q2 2026, filed 13 Aug 2026.